RxDoctor Payments Data

Teresa Britt, PA

Physician Assistant · Cary, NCNPI 1679125439

Payments from drug & device makers

$5,604in general payments, 2019–2025

Across 298 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$943
  • Lilly USA, LLC$793
  • Pfizer$254
  • Johnson & Johnson$219
  • Takeda Pharmaceuticals U.S.A., Inc.$204
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$5,595100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,604 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,420
Medicare patients
111
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$60,792
TrulicityDulaglutide26$29,552
JardianceEmpagliflozin21$26,694
OzempicSemaglutide11$9,737
Advair HfaFluticasone Propion/Salmeterol12$3,319
SynthroidLevothyroxine Sodium17$2,139
Levothyroxine Sodium110$2,063
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,602
Estradiol33$1,528
Pantoprazole Sodium67$1,301
Rosuvastatin Calcium121$1,282
Losartan Potassium147$1,230
Olmesartan Medoxomil58$1,091
Duloxetine Hcl58$1,073
Gabapentin62$955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$793$90,34376 claims
Boehringer IngelheimJardiance$80$26,69421 claims
Novo NordiskOzempic$943$9,73711 claims
AbbVieSynthroid$1,502$2,13917 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$2,063110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →